A grey area within bioethics presents some very challenging questions as it becomes increasingly harder to distinguish what is moral and immoral in the realm of science. Join Darshan Kulkarni as he talks about the importance of bioethics, and some...
Not all products have to meet the U.S. Federal Drug Administration’s (FDA) approval: certain biologics and dietary supplements do not require it, and there are alternative pathways for OTC drugs and other products to skip the process.
Drugmakers have become increasingly entangled in kickback and bribery schemes, and as a consequence, face millions in settlement to the U.S. government.
The US Food and Drug Administration (FDA) has announced new restrictions concerning the marketing of tobacco products such as e-cigarettes and vape pens in an effort to mitigate risks to public health.
Opioid drugmakers Insys Therapeutics and Mallinckrodt Pharmaceuticals face millions of dollars in settlement as a consequence of allegedly bribing doctors to prescribe their drugs.
US Food and Drug Administration (FDA) cracks down on false claims--issuing warning letters to companies for marketing supplements as valid treatment options for Alzheimer’s disease.
